Discovery of huperzine A-tacrine hybrids as potent inhibitors of human cholinesterases targeting their midgorge recognition sites

Journal of Medicinal Chemistry

Volumn 49, Issue 11, 2006, Pages 3421-3425

  Gemma, Sandra ^a   Gabellieri, Emanuele ^a   Huleatt, Paul ^a   Fattorusso, Caterina ^a   Borriello, Marianna ^a   Catalanotti, Bruno ^a   Butini, Stefania ^a   De Angelis, Meri ^a   Novellino, Ettore ^a   Nacci, Vito ^a   Belinskaya, Tatyana ^b   Saxena, Ashima ^b   Campiani, Giuseppe ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 [7 (1,2,3,4 TETRAHYDROACRIDIN 9 YLAMINO)HEPTYLAMINO] 9 ETHYLIDENE 3 METHYLBICYCLO[3.3.1]NON 3 ENE 1 CARBOXYLIC ACID; ACETYLCHOLINESTERASE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; HUPERZINE A; N1 [7 (1,2,3,4 TETRAHYDROACRIDIN 9 YLAMINO)HEPTYL] 9 ETHYLIDENE 4,4,7 TRIMETHYLBICYCLO[3.3.1NON 6 ENE 1,3 DIAMINE; N1 [7 (1,2,3,4 TETRAHYDROACRIDIN 9 YLAMINO)HEPTYL] 9 ETHYLIDENE 7 METHYLBICYCLO[3.3.1]NON 6 ENE 1,3 DIAMINE; TACRINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BINDING SITE; CHOLINESTERASE INHIBITION; DISSOCIATION CONSTANT; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; PROTON NUCLEAR MAGNETIC RESONANCE;

ACETYLCHOLINESTERASE; BINDING SITES; BUTYRYLCHOLINESTERASE; CATALYTIC DOMAIN; CHOLINESTERASE INHIBITORS; HUMANS; MODELS, MOLECULAR; PROTEIN BINDING; SESQUITERPENES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TACRINE;

EID: 33744830048     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060257t     Document Type: Article

References (23)

1. Gentry, M. K.; Doctor, B. P. In Cholinesterases: Structure, function, mechanism, genetics, and cell biology; Massoulie, J., Bacou, F., Barnard, E. A., Chatonnet, A., Doctor, B. P., Eds.; American Chemical Society: Washington, DC, 1991; pp 394-398.
2. Saxena, A.; Redman, A. M. G.; Jiang, X.; Lockridge, O.; Doctor, B. P. Differences in active site gorge dimension of cholinesterases revealed by binding of inhibitors to human butyrylcholinesterase. Biochemistry 1997, 36, 14642-14651.
3. Giacobini, E. Cholinergic functions in Alzheimer's disease. Int. J. Geriatr. Psychiatry 2003, 18, S1-S5, and references therein.
4. Greig, N. H.; Utsuki, T.; Yu, Q.-S.; Zhu, X.; Holloway, H. W.; Perry, T.; Lee, B.; Ingram, D. K.; Lahiri, D. K. A new therapeutic target in Alzheimer's disease treatment: Attention to butyrylcholinesterase. Curr. Med. Res. Opin. 2001, 17, 1-6.
5. Mesulam, M. M.; Guillozet, A.; Shaw, P.; Levey, A.; Duysen, E. G.; Lockridge, O. Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyse acetylcholine. Neuroscience 2002, 110, 627-639.
6. Kuhl, D. E.; Koeppe, R. A.; Snyder, S. E.; Minoshima, S.; Frey, K. A.; Kilbourn, M. R. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses. Ann. Neurol. 2006, 59, 13-20.
7. (a) Lane, R. M.; Potkin, S. G.; Enz, A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia. Int J. Neuropsychopharmacol. 2006, 1, 101-124.
8. (b) Bartorelli, L.; Giraldi, C.; Saccardo, M.; Cammarata, S.; Bottini, G.; Fasanaro, A. M.; Trequattrini, A. Effects of switching from an AChE inhibitor to a dual AchE-BuChE inhibitor in patients with Alzheimer's disease. Curr. Med. Res. Opin. 2005, 11, 1809-1818.
9. Jiang, H.; Luo, X.; Bai, D. Progress in clinical, pharmacological chemical and structural biological studies of huperzine A: A drug of traditional Chinese medicine origin for the treatment of Alzheimer's disease. Curr. Med. Chem. 2003, 10, 2231-2252.
10. Pang, Y.-P.; Quiram, P.; Jelacic, T.; Hong, F. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J. Biol. Chem. 1996, 271, 23646-23649.
11. Savini, L.; Gaeta, L.; Fattorusso, C.; Catalanotti, B.; Campiani, G.; Chiasserini, L.; Pellerano, C.; Novellino, E.; McKissic, D.; Saxena, A. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors. J. Med. Chem. 2003, 46, 1-4.
12. Campiani, G.; Fattorusso, C.; Butini, S.; Gaeta, A.; Agnusdei, M.; Gemma, S.; Persico, P.; Catalanotti, B.; Savini, L.; Nacci, V.; Novellino, E.; Holloway, W.; Greig, N. H.; Belinskaya, T.; Fedorko, J. M.; Saxena, A. Development of molecular probes for the identification of extra interaction sites in the mid-gorge and peripheral sites of butyrylcholinesterase (BuChE). Rational design of novel selective, and highly potent BuChE inhibitors. J. Med. Chem. 2005, 48, 1919-1929.
13. (a) Campiani, G.; Sun, L. Q.; Kozikowski, A. P.; Aagaard, P.; McKinney, M. A palladium-catalyzed route to huperzine A and its analogues and their anticholinesterase activity. J. Org. Chem. 1993, 58, 7660-7669.
14. (b) Kozikowski, A. P.; Campiani, G.; Sun, L.-Q.; Wang, S.; Saxena, A.; Doctor, B. P. Identification of a more potent analogue of the naturally occurring alkaloid huperzine A. Predictive molecular modeling of its interaction with AChE. J. Am. Chem. Soc. 1996, 118, 11357-11362.
15. (c) Kozikowski, A. P.; Campiani, G.; Tückmantel, W. An approach to open chain modified heterocyclic analogues of the acetylcholinesterase inhibitor, Huperzine A, through a bicyclo[3.3.1]nonane intermediate. Heterocycles 1994, 39, 101-116.
16. (d) Gemma, S.; Butini, S.; Fattorusso, C.; Fiorini, I.; Nacci, V.; McKissic, D.; Saxena, A.; Campiani, G. A palladium-catalyzed synthetic approach to new huperzine A analogues modified at the pyridone ring. Tetrahedron 2003, 59, 87-93.
17. Camps, P.; Cusack, B.; Mallender, W. D.; El Achab, R.; Morral, J.; Munoz, D. T.; Rosenberry, T. L. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Mol. Pharmacol. 2000, 57, 409-417.
18. Carlier, P. R.; Du, D.-M.; Han, Y.; Liu, J.; Pang, Y.-P. Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 2335-2338.
19. Nelson, L. A. K.; Shaw, A. C.; Abrams, S. R. Synthesis of (+)-, (-)-, and (±)-7′-hydroxyabscisic acid. Tetrahedron 1991, 47, 3259-3270.
20. Mander, L. N.; Sethi, S. P. Regioselective synthesis of β-ketoesters from lithium enolates and methyl cyanoformate. Tetrahedron Lett. 1983, 5425-5428.
21. Sreeknmar, C.; Darst, K. P.; Still, W. C. A direct synthesis of Z-trisubstituted allylic alcohols via the Wittig reaction. J. Org. Chem. 1980, 45, 4260-4262.
22. Carlier, P. R.; Chow, E. S.-H.; Han, Y.; Liu, J.; Yazal, J.; Pang, Y.-P. Heterodimeric tacrine-based acetylcholinesterase inhibitors: Investigating ligand-peripheral site interactions. J. Med. Chem. 1999, 42, 4225-4231.
23. Wagermann, R.; Vilsmaier, E.; Maas, G. Spatially fixed oligoamines IV. 1 flexibility and protonation of meander-type octamines. Tetrahedron 1995, 8815-8826.